Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers

Palo Alto, California, Needham, Massachusetts and Melbourne, Australia – January 8, 2025 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced positive results from a recently completed Phase 1 study of BRB-002 in healthy volunteers. BRB-002 is a first-in-class, immune modulating protein therapy that targets CD47 for treatment […]